WORCESTER, Mass.--(BUSINESS WIRE)--Biovest International, Inc. (OTCBB:BVTI) today announced that the U.S. Federal Government has approved the appropriation of $1.6 million in biomedical research funds for Fiscal Year 2009 for the Defense Department's Cancer Immunotherapy and Cell Therapy Initiative, which is intended to support research into new applications for the AutovaxID™ instrument, Biovest's fully-automated cell-manufacturing device to cost-effectively and efficiently manufacture difficult-to-produce therapeutic proteins and personalized vaccines, including vaccines targeting cancers.
